AXL and B-cell chronic lymphocytic leukemia: While pretreatment of CLL cells with an AXL inhibitor reduced H2O2-induced AKT/ERK activation levels in both the samples, asciminib completely inhibited P-AKT level in CLL cells from one patient but not in other (Supplementary Fig. S2).